Insider Stock Transactions at Aehr Test Systems
Several executives at Aehr Test Systems, including the CEO, reported routine stock transactions on October 27, 2026, related to tax withholding.
Stocks · News reference
QUICK SPARK: Russell 2000 Hits New Record Highs, Beats Nasdaq 100 In 2026
The Russell 2000 hits a record high as small caps outperform the Nasdaq 100, led by three companies, including AN2 Therapeutics.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of semiconductor and chip companies are trading higher as the sector rebounds from last week's weakness, with CoreWeave, the bellwether, rising on a Goldman Sachs upgrade. The Philadelphia Semiconductor Index is expected to end its longest losing streak since the 2008 financial crisis.
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis.
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. announced the grant of inducement equity awards to two newly hired employees.
AN2 Therapeutics to Present Phase 2 Trial Design for Epetraborole in Polycythemia Vera
AN2 Therapeutics announced it will present the design of its planned Phase 2 clinical trial for epetraborole in patients with polycythemia vera at the 18th International Congress on Myeloproliferative Neoplasms.